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INTRODUCTION
Patients chronically infected by hepatitis C 
virus (HCV) present various immune-medi-
ated phenomena mainly due to B lymphocyte 
dysfunction as mixed cryoglobulinemia and 
non-organ-specifi c autoantibodies (NOSAs) 
production.1,2 Although cryoglobulinemia has 
been associated with vasculitis of small and 
medium-size vessels and glomerulonephri-
tis, the involvement of NOSAs in the immu-
nopathology of hepatitis C is not completely 
understood. However, the presence of smooth 
muscle antibodies (SMA) has been reported to 
be higher in cryoglobulinemic HCV carriers, 
whereas cryoglobulinemia has been associated 
with advanced liver fi brosis and poor response 
to antiviral therapy with interferon-α.3,4
In this study we report the association be-
tween SMA, cryoglobulinemia and liver fi bro-
sis in untreated Brazilian HCV carriers.
PATIENTS AND METHODS
Patients
Sixty-fi ve consecutive untreated HCV carriers 
(38 women and 27 men), with a mean age of 
51.3 ± 13.9 years (ranging from 20 to 67 years), 
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from two hepatitis reference centers in Salvador 
(Bahia, Brazil) were included in this study. They 
tested positive for serum anti-HCV antibodies 
by enzyme-linked immunosorbent assay with 
structural and non-structural HCV antigens 
(AXSYM System; Abbott Laboratories, Chicago, 
IL, USA) and for HCV-RNA by polymerase 
chain reaction (PCR) (AmplicorTM HCV Detec-
tion KIT V2.0; Roche Molecular Systems Inc., 
Somerville, NJ, USA). The median ALT level was 
56 U/L and 65.5 U/L for the women and men, 
respectively. Forty-fi ve carriers were infected 
with HCV genotype 1, and 20 with the genotype 
3 as determined by the INNOLIPA test (Innoge-
netics, NV, Gent, Belgium). 
An informed consent was signed by all pa-
tients to participate in the study, which was ap-
proved by the Ethical Committee of Universi-
dade Estadual de Santa Cruz, Bahia, Brazil.
Liver histopathology
Histology of liver biopsy specimens was per-
formed by a single experienced liver pathologist 
in samples stained by hematoxylin-eosin, Picro-
sirius red, and Perls stains. To avoid bias, the clini-
cal background of the donors of liver biopsies was 
not known by this professional before the exams. 
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The histological abnormalities in liver biopsy were clas-
sifi ed in accordance with the METAVIR system:5 F0, no fi -
brosis; F1, portal fi brosis without septa; F2, few septa; F3, 
numerous septa without cirrhosis; and F4, cirrhosis. Necro-
inﬂ ammatory activity was graded on a scale of A0-A3, cor-
responding A0 to no histological activity; A1, mild activity; 
A2, moderate activity; and A3, severe activity.
Cryoglobulinemia and SMA 
Cryoglobulin was investigated using both tube and gel cryopre-
cipitation.6 Smooth muscle IgG antibodies were tested by indi-
rect ﬂ uorescent antibody test using antigenic substrates of ro-
dent rat liver–kidney–stomach sections and sera diluted at 1:40. 
Statistical analysis
The association between two or more categorical groups was 
analyzed by the Exact Fisher test or the chi-square test, us-
ing the statistical software SPSSTM version 16.0 for Windows. 
A p-value < 0.05 was considered signifi cant.
RESULTS
Varied degrees of fi brosis were observed in the HCV carriers. 
Forty-four out of 65 (67.7%) carriers had mild to moderate 
fi brosis (F1-F2), 16 out of 65 (32.3%) had advanced fi brosis 
(F3) and fi ve (7.7%) had cirrhosis (F4). No inﬂ ammatory 
activity (A0) was observed in 13 HCV carrier. Seven of them 
had a mild inﬂ ammatory activity (A1), 30 presented a mod-
erate activity (A2) and in only two individuals it was severe. 
Smooth muscle antibodies were detected in 22 out of 65 
(33.8%) HCV carriers and cryoglobulinemia was found in 
24 out of 65 (36.9%) patients. Advanced liver fi brosis (F3-
F4) was associated with the presence of smooth muscle anti-
bodies (Fisher exact test, p = 0.048), and progression to ad-
vanced liver fi brosis with the presence of cryoglobulinemia 
(chi-square test, p = 0.031) (Figure 1).
Neither smooth muscle antibodies nor cryoglobuline-
mia was associated with hepatocellular inﬂ ammatory activ-
ity, age, carrier gender or any HCV genotype.
DISCUSSION
In this study, we demonstrated the association of SMA 
and cryoglobulinemia with liver fibrosis in Brazilian 
HCV carriers. Smooth muscle antibodies are immuno-
globulins that react with filaments of the cytoskeleton, 
which are represented by microfilaments (actin and vin-
culin), intermediate filaments (vimentin and desmin) 
and microtubules (tubulin). Although these autoanti-
bodies are more commonly detected in autoimmune 
hepatitis, mainly anti-actin antibodies, they may also be 
found in low titers and varied prevalence in normal in-
dividuals and in patients presenting different infections, 
cancer and systemic autoimmune diseases. Smooth mus-
cle antibodies are frequently detected in sera of HCV 
carriers as previously reported by several authors, with a 
prevalence varying from 10% to 55%.6 The prevalence of 
SMA found in HCV carriers in this work was in accord-
ance with the findings of a previous Brazilian study and 
also in accordance with the reports of hepatitis C studies 
performed in different countries.7-9
Hepatic fibrosis is caused by a complex immune 
mechanism, influenced by genetic and environmental 
factors, which involves cytokines as TGF-beta, angioten-
sin II and leptin. Inflammatory cells as polymorphonu-
clear cells and lymphocytes, and also activated hepatic 
stellate cells, portal fibroblasts and myofibroblasts par-
ticipate in this process that culminates with excessive 
secretion of matrix proteins including collagen.10 Our 
results found the association between SMA seroposi-
tivity and advanced fibrosis (F3-F4) that may be an 
additional evidence of the involvement of the Th2 im-
mune response in the active fibrogenesis as previously 
revised.11 The association between SMA and advanced 
fibrosis was also reported in a recent study performed 
with French HCV carriers, which also demonstrated an 
association between the presence of SMA and hepatocel-
lular necrosis and inflammation,12 a finding that was not 
verified in our work. Such a divergence related to hepatic
Figure 1: Distribuition of liver fibrosis score in HCV carries seropositive and seronegative for cryoglobulinaemia. 
Cryoglobulinaemia was associated with liver fibrosis progression (chi-square test, p < 0.05).
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necroinflammation may be caused by ethnic difference 
in the populations studied or by difference in the genetic 
background of the HCV carriers investigated. This pos-
sibility may be supported by the association of smooth 
muscle antibodies with HLA A1-B8-DR3 haplotype.13 
Nevertheless, the involvement of molecular homology 
between HCV proteins and human self-antigens in the 
production of SMA has been documented.14 
Cryoglobulinemia is the main extra-hepatic mani-
festation of chronic hepatitis C, which is caused by a 
dysfunction of B-lymphocyte and is immunochemically 
characterized by a cryoprecipitable immune complex 
formed by rheumatoid factor and IgG antibodies linked 
to HCV core antigen. Its prevalence varies from 29% to 
54% in HCV carriers, and has been clinically associated 
with leg ulcers, vasculitis, palpable purple skin lesions 
and glomerulonephritis.15 The statistically significant 
association between CM positivity and advanced fibro-
sis in our study was in agreement with results of a Greek 
study that reported an association between cryoglobu-
linemia and staging score of chronic HCV infection.4 
Nevertheless, this association is still controversial and 
need more studies to elucidate and establish the link be-
tween these two immunopathological aspects of chronic 
hepatitis C.
We concluded that liver histology should be performed 
in untreated HCV carriers that are seropositive for either 
smooth muscle antibodies or cryoglobulinemia. 
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